Evaluation of the depth of sedation under different regimes of Dexmedetomidine application in drug induced sleep endoscopy (DISE) in sleep disordered breathing

Evaluation of the depth of sedation under different regimes of Dexmedetomidine application in drug induced sleep endoscopy (DISE) in sleep disordered breathing - DEXENDO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028606

Enrollment

100

Registered

2022-04-08

Start date

2022-05-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G47.3 R06.5

Interventions

Group 1: 1,4ug/kg/h Dexmedetomidine Perfusor-application i.v. Group 2: 1,2ug/kg/h Dexmedetomidine Perfusor-application i.v. Group 3: 1,0ug/kg/h Dexmedetomidine Perfusor-application i.v. Group 4: 0,8ug

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: none

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Duration of investigation (time) - Termination of the investigation is defined by a plateau level of the sedation monitoring - Depth of sedation is monitored by BIS	—

Secondary

Measure	Time frame
Course of the sedation	—

Countries

Germany

Contacts

Public ContactMichael Herzog

Carl-Thiem-Klinikum

m.herzog@ctk.de0355462849

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026